Master Research and Development Agreement under which Viriom provided virology services; Company incurred R&D expense for Viriom services
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Iain Dukes
Also a director
Chief Executive Officer, Secretary and Director
|
67 | Not stated | Not stated | $1,401,924 | |
|
Charles Parker
Chief Financial Officer
|
45 |
Since 2025
1 year
|
Not stated | Not reported | |
|
Nikolay Savchuk
Also a director
Chief Operating Officer and Director
|
57 | Not stated | Not stated | $734,810 | |
|
Robert R. Redfield
Chief Medical Officer
|
74 |
Since 2024
2 years
|
Not stated | Not reported | |
|
C. David Pauza
Chief Science Officer, Virology
|
72 |
Since 2024
2 years
|
Not stated | Not reported | |
|
Victor Moyo
Chief Medical Officer, Oncology
|
58 |
Since 2024
2 years
|
2023 | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Master Research and Development Agreement under which Viriom provided virology services; Company incurred R&D expense for Viriom services
Asset Purchase Agreement under which the Company bought certain pyrrolidine antiviral compound intellectual property assets from Viriom
Exclusive royalty-free license to Viriom patents and technical information; no annual fees, royalties or milestone payments required
Master Research and Development Agreement under which ChemDiv provided preclinical drug discovery services; Company incurred R&D expense
Master Research and Development Agreement under which Expert provided drug development and consulting services; R&D expense recorded
Securities purchase of Company common stock and Series C Preferred Stock in connection with the Trawsfynydd acquisition
Purchase of Class B Units (pre-funded warrants and Series A Warrants) under the December 2024 Purchase Agreement
Purchase of Class B Units (pre-funded warrants and Series A Warrants) under the December 2024 Purchase Agreement
Purchase of common stock and Series A, B and C warrants under a securities purchase agreement with certain investors
Loading...